Comparison of treatment with ⁸⁹SrCl₂ and ¹⁵³Sm-ethylenediaminetetramethylene phosphate in metastatic cancers of bone

Objective To evaluate the effect of ⁸⁹SrCl₂ and ¹⁵³Sm-ethylenediaminetetramethylene phosphonate (¹⁵³Sm-EDTMP) on metastatic carcinoma of bone. Methods All patients with widespread metastatic bone cancers were divided into two groups randomly:sixty-nine patients were treated with ⁸⁹SrCl₂ with dose of 1.11~2.22 MBq/kg by intravenous injection, fifth-one patients were treated with ¹⁵³Sm-EDTMP with dose of 25.9~37.0 MBq/kg by the same way. Bone imaging was analized in 3~6 months. The pain, the metastasis varied situation, and side-effect were compared. Results In the group of ⁸⁹SrCl₂ the remission rats of bone pain of positive response, total-effect, apparent, finess, no-effect was 92.8%, 69.6%, 23.3%, 7.2% respectively. In the group of ¹⁵³Sm-EDTMP, the data were 94.2%, 66.7%, 27.5%, 5.8% respectively. There were not significantly different between groups of ⁸⁹SrCl₂ and ¹⁵³Sm-EDTMP (χ²=4.98, P>0. 05). In group of ⁸⁹SrCl₂ the rate of area of skeletal metastases Grade Ⅰ (disappear, reduction, maintain and no-new-development) was 56.5%. However it was, in ¹⁵³Sm-EDTMP group, 54.9%. There was no significantly difference between ⁸⁹SrCl₂ and ¹⁵³Sm-EDTMP groups (χ²=4.81, P>0.05). The arrest rate of bone marrow (white blood or blood platelet was descended) of ⁸⁹SrCl₂ group was 40.8% while in ¹⁵³Sm-EDTMP group was 59.2%. There was a significantly different between them (χ²=7.45, P<0.05). Conclusion ⁸⁹SrCl₂ and ¹⁵³Sm-EDTMP have effect on metastatic carcinoma of bone treatment. It is suggested that one can choose each of them by economic condition. But, ⁸⁹SrCl₂ can maintain the effect in a long time and bone marrow is arrested serious, so it is the first choise for early metastatic carcinoma of bone.